Breaking News Instant updates and real-time market news.

RCUS

Arcus Biosciences

$14.34

-0.71 (-4.72%)

06:21
04/09/18
04/09
06:21
04/09/18
06:21

Arcus Biosciences initiated with a Buy at Citi

Citi analyst Robyn Karnauskas started Arcus Biosciences with a Buy rating and $25 price target. The analyst says that while lead compound data is not expected until the first half of 2019, Arcus' proven management and drugs targeting validated pathway make the company competitive despite the crowded landscape in solid tumors.

  • 14

    Apr

RCUS Arcus Biosciences
$14.34

-0.71 (-4.72%)

04/09/18
GSCO
04/09/18
INITIATION
Target $18
GSCO
Neutral
Arcus Biosciences initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter started Arcus Biosciences with a Neutral rating and $18 price target. The analyst sees a lack of near-term pipeline catalysts for the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.